Neal Gerber Eisenberg and Wolters Kluwer have teamed up to bring you NGE IP Focus, a quarterly newsletter dedicated to intellectual property-related legal decisions.
...more
1/24/2019
/ Gilead Sciences ,
Intellectual Property Protection ,
Inventions ,
Life Sciences ,
Obviousness ,
Opioid ,
Pain Management ,
Patent Infringement ,
Patent Invalidity ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Section 101
On April 15, 2016, Kevin A. O’Connor, Ph.D and Kevin C. May, partners in the Intellectual Property & Technology Transactions practice group, filed an amicus brief in the United States Court of Appeals for the Federal Circuit...more